Novel coagulation biomarkers in high-risk cardiovascular population
- Years funded:
- 2018 - 2020
Cardiovascular diseases are the leading causes of death in the world, with an estimated 17.3 million deaths annually.
While significant progress has been made in the treatment of cardiovascular disease (CVD), the ability to evaluate the risk of thrombosis has not been well elucidated and is limiting our capacity to develop and monitor new treatments.
Current available laboratory investigations only provide information about the time to the start of clotting, which accounts for only <5% of clot formation, without assessing the other crucial aspects of thrombosis including total clot formation, vessel wall function, platelet function as well as the role of genetic modulation of the thrombotic response.
New experimental global coagulations assays such as the calibrated automated thrombogram (CAT) calculates the thrombin generation (i.e. total clot formation) and provides a more accurate global assessment of coagulation.
This prospective study aims to improve our evaluation of clotting pathways in cardiovascular medicine through the use of global coagulation assay and novel coagulation biomarkers, as well as demonstrate the compensatory mechanism between the different arms of the Virchow’s triad in cardiovascular diseases.
The ability to evaluate these new biomarkers will also provide a holistic understanding of an individual's true clotting risk and will assist in prevention and monitoring of cardiovascular diseases.
Dr Hui Yin Lim
|Institute:||Florey Institute of Neuroscience and Mental Health|